Proteus By Seqens Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
Proteus By Seqens General Information
Description
Developer of advanced protein engineering technologies intended to optimize enzymes and biocatalytic processes for industrial applications. The company offers a diverse microorganism collection, patented enzyme evolution technologies, and scalable bioprocess development capabilities, enabling industries such as pharmaceuticals, fine chemicals, and personal care to enhance production efficiency while providing sustainable and tailored biocatalytic options for specific market needs.
Contact Information
Website
proteus.seqens.comCorporate Office
- 23 rue Bossuet
- ZI de la Vigne aux Loups
- 91160 Longjumeau
- France
Corporate Office
- 23 rue Bossuet
- ZI de la Vigne aux Loups
- 91160 Longjumeau
- France
Proteus By Seqens Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 25-Apr-2006 | Completed | Generating Revenue | |||
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Proteus By Seqens Patents
Proteus By Seqens Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3133039-A1 | Pesticidal genes and methods of use | Pending | 13-Mar-2019 | ||
| EP-3708669-A1 | Pesticidal genes and methods of use | Inactive | 13-Mar-2019 | ||
| US-20220185850-A1 | Pesticidal genes and methods of use | Active | 13-Mar-2019 | ||
| WO-2020183022-A1 | Pesticidal genes and methods of use | Inactive | 13-Mar-2019 | ||
| FR-3047742-A1 | Gelified composition of tetrazolium salt and gellane gum | Inactive | 11-Feb-2016 | C12Q1/045 |
Proteus By Seqens Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Proteus By Seqens Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ardian France | PE/Buyout | Minority | ||
| BIC Innov'up | Accelerator/Incubator | |||
| Soridec | Venture Capital | Minority |
Proteus By Seqens FAQs
-
When was Proteus By Seqens founded?
Proteus By Seqens was founded in 1998.
-
Where is Proteus By Seqens headquartered?
Proteus By Seqens is headquartered in Longjumeau, France.
-
What is the size of Proteus By Seqens?
Proteus By Seqens has 20 total employees.
-
What industry is Proteus By Seqens in?
Proteus By Seqens’s primary industry is Biotechnology.
-
Is Proteus By Seqens a private or public company?
Proteus By Seqens is a Private company.
-
What is Proteus By Seqens’s current revenue?
The current revenue for Proteus By Seqens is .
-
Who are Proteus By Seqens’s investors?
Ardian France, BIC Innov'up, and Soridec have invested in Proteus By Seqens.
-
When was Proteus By Seqens acquired?
Proteus By Seqens was acquired on 25-Apr-2006.
-
Who acquired Proteus By Seqens?
Proteus By Seqens was acquired by PCAS.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
